Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
N Engl J Med
.
2025 Aug 21;393(8):823-825.
doi: 10.1056/NEJMc2504588.
Authors
Adolfo Aleman
1
,
Oliver Van Oekelen
1
,
David T Melnekoff
1
,
Leah Grossman
1
,
Tarek H Mouhieddine
1
,
Agata Kurowski
1
,
Ivan Odak
1
,
Sidorela Reci
1
,
Shriya Desai
1
,
Shannon Meledathu
1
,
Malini P Naidu
1
,
Ravi P Shukla
1
,
Rudra P Dutta
1
,
Katerina Kappes
1
,
Kseniya Serebryakova
1
,
Hayley Jackson
1
,
Jordan Lu
1
,
Anastasia Chatikhine
1
,
Raksha Kulkarni
1
,
Zahra Moinfar
1
,
Matthew M Croken
1
,
Meenakshi Mehrotra
1
,
Brett Baskovich
1
,
Sampanna Rayamajhi
1
,
Shambavi Richard
1
,
Adriana C Rossi
1
,
Christian Salib
1
,
Jane Houldsworth
1
,
Brian D Brown
1
,
Miriam Merad
1
,
Alessandro Laganà
1
,
Patrick M Brunner
1
,
Sundar Jagannath
1
,
Joshua D Brody
1
,
Samir Parekh
1
Affiliation
1
Icahn School of Medicine at Mount Sinai, New York.
PMID:
40834307
PMCID:
PMC12370277
DOI:
10.1056/NEJMc2504588
No abstract available
Publication types
Letter
Grants and funding
R37 CA246239/CA/NCI NIH HHS/United States
R01/R37 CA246239/CA/NCI NIH HHS/United States
HONORS award/American Society of Hematology
UL1TR004419/TR/NCATS NIH HHS/United States
R01 CA252222/CA/NCI NIH HHS/United States
R38 HL172261/HL/NHLBI NIH HHS/United States
UL1 TR004419/TR/NCATS NIH HHS/United States
R01 CA244899/CA/NCI NIH HHS/United States
P30 CA196521/CA/NCI NIH HHS/United States
R38HL172261/HL/NHLBI NIH HHS/United States
K12 CA270375/CA/NCI NIH HHS/United States
R01 CA290791/CA/NCI NIH HHS/United States